Reduction of Hemorrhagic Complications After Nonfocal Renal Biopsy with Pre-Procedure Desmopressin Administration

Sunday, April 12, 2026

3:09 PM - 3:18 PM ET

Location: 701A

Presenting Author(s)

Amy R. Deipolyi, MD, PhD, FSIR

Division Chief, IR
West Virginia University, West Virginia, United States

Author/Co-author(s)

BD

Bradford Dugan, BS

Medical Student
West Virginia University School of Medicine, West Virginia, United States
CW

Christine Welch, PhD

Biostatistician
Institute of Academic Medicine, Charleston Area Medical Center, West Virginia, United States
AR

Asif Rahman, MD

Nephrologist
Charleston Area Medical Center Nephrology, West Virginia, United States
MK

Michael Korona, MD

Interventional Radiologist
Interventional Radiology, Department of Surgery, Charleston Area Medical Center, West Virginia, United States

Purpose: To evaluate the safety and efficacy of desmopressin (DDAVP) administration prior to NFRB to mitigate bleeding risk.

Materials and Methods: This retrospective observational study included all 158 patients who underwent NFRB from 3/2022—6/2025, before and after implementation of a DDAVP administration protocol. In 7/2023, every patient regardless of renal function received 0.3 mcg/kg intravenous DDAVP immediately before biopsy, involving 18-gauge cores through coaxial guides. Patients who did or did not receive DDAVP were compared using Mann-Whitney U tests for nonparametric data, Student’s t tests for parametric data, and chi-square tests for categorical data, (alpha level of P< 0.05).

Results: Of 158 patients, 79 received DDAVP and 79 did not. Sodium was not significantly different at pre- or post-procedure, p = 0.61 and 0.45, respectively. Hemoglobin values were not different pre procedure and with fewer post procedure values the difference pre to post was not significant. Blood transfusion rate (10.1%) was the same for both groups. Six/79 (8%) patients who underwent NFRB without DDAVP had an unplanned admission and/or angiography within 1 week of biopsy, compared to 0 in the DDAVP group (P=0.03). There was no difference in the rate of thromboembolic events between groups (2/79 [2.5%] v. 3/79 [3.8%]; P=1.00). All 5/158 (3.2%) patients who had stroke or a myocardial infarction within 1 week of NFRB had been on anticoagulant or antiplatelet agents that were held for biopsy.

Conclusion: DDAVP was associated with reduced unplanned hospitalizations and angiography/embolization after NFRB without increasing the risk of thromboembolic events.